Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Xalkori TM
Listen to the Pronunciation:
Active ingredients: crizotinib
What it is used for
XALKORI is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). XALKORI is indicated for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Store at room temperature
- Shelf lifetime is 48 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Hard gelatin capsule with white opaque body and pink opaque cap, printed with black ink Pfizer on the cap, CRZ 200 on the body.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on February 1, 2021. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient crizotinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Genetic testing for cancer information | myVMC
Inherited genetic mutations increase the risk of certain cancers. Genetic testing is used to group cancers and develop new targeted cancer therapies.
Read more on myVMC – Virtual Medical Centre website
Top results
The challenge of costly drugs | Issue 3 | Volume 39 | Australian Prescriber
The Pharmaceutical Benefits Scheme costs Australia over $9 billion. Are taxpayers receiving value for money? Read about the challenges of providing uniform...
Read more on Australian Prescriber website
